{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiahkfycgqkbtvb2hql2bvcckcbsnau54gwef74ika3j5caac2zbzi",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mhih7i6b46s2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihsnbsxz5kcvqdmb5pvs43vfu2xcyfotvntvo5ry6vkhjcp5g3pga"
    },
    "mimeType": "image/jpeg",
    "size": 60551
  },
  "path": "/2026/03/20/uk-nice-leqembi-kisunla-alzheimers-price-cost-effective/?utm_campaign=rss",
  "publishedAt": "2026-03-20T11:05:24.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Alzheimer’s",
    "Pharmaceuticals",
    "Policy",
    "STAT+"
  ],
  "textContent": "Following successful appeals from drugmakers, the U.K. is taking another look at whether two new Alzheimer's drugs can be considered cost-effective.",
  "title": "STAT+: U.K. to take another look at cost-effectiveness of Alzheimer’s drugs",
  "updatedAt": "2026-03-20T11:42:33.000Z"
}